We presented results from a retrospective natural history study evaluating disease progression in transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) patients with familial amyloidotic cardiomyopathy (FAC). These results were presented at a meeting with members of the Association of Black Cardiologists (ABC) at the American College of Cardiology (ACC) Annual Scientific Session, held March 14 – 16, 2015. Amongst other findings, study results showed a mean decline of 140 meters in 6-minute walk distance (6-MWD) over an 18-month period in FAC patients with mild-to-moderate heart failure. Also at the ACC meeting, we presented complete results from our Phase 2 clinical trial with revusiran, an investigational RNAi therapeutic for the treatment of FAC. Consistent with preliminary results
presented last year, revusiran achieved an up to 98.2% knockdown of serum TTR – the disease-causing protein – and was found to be generally well tolerated.
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=901611" type=" "] Read our press release[/spotlight-link]
[spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/FAC-NH-Presentation-for-ABC-meeting_15Mar20151.pdf" type="(2 MB PDF)"]View the FAC Natural History Study presentation[/spotlight-link]
[spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/Revusiran-ACC-15Mar2015.pdf" type="(406 KB PDF)"]View the complete revusiran Phase 2 results[/spotlight-link]